

**REMARKS:**

In the Office Action dated May 3, 2007, claims 1-31, in the above-identified U.S. patent application were subject to restriction. Applicants hereby elect group I, claims 1-21 directed to the use of a single stranded RNA molecule for inhibiting the expression of a target transcript, a pharmaceutical composition and a method of prevention or treatment, with traverse. Applicants point out that claims 1-19 are use claims which were filed in Europe because method of treatment claims are not permitted in Europe (the present application is a 371 of PCT/EP03/07516). The use claims in the present application should be interpreted as method claims. Claims 1-19 have been amended to clarify this.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By /Monica Chin Kitts/

Monica Chin Kitts  
Attorney for Applicant  
Registration No. 36,105  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

MCK/